Tokyo Institute of Technology

Nof Corporation

The University of Tokyo

Osaka University

Keio University

Sbi Pharmaceuticals Co., Ltd.

Nanocarrier Co., Ltd.

Stella Pharma Corporation

Takahiro Nomoto

Nobuhiro Nishiyama

Hiroyasu Takemoto

Makoto Matsui

Keishiro Tomoda

Hiroki Yoshioka

Yuji Yamamoto

Naoki Yamada

Masaki Kamiya

Midori Hirai

Akiko Sasaki

Kazuki Miyauchi

Kazunori Kataoka

Kanjiro Miyata

Yasuki Kato

Masaki Mori

Shigeto Fukushima

Hideyuki Saya

Mika Hamura

Yu Matsumoto

Osamu Nagano

Kazuki Osakama

Hideshi Ishii

Yuto Honda

Kana Kohmoto

Abdul-Hackam Ranneh

Kentaro Suina

Tsukasa Nishimori

Ronald James Christie

Yukiya Inoue

Ying Yao

Kaito Kanamori

Masamitsu Konno

Kenji Tsuchihashi

Takanori Inaba

Xiaohang Sun

A conjugate is provided in which a deferoxamine-type compound, which is at least one compound selected from the group consisting of deferoxamine or an ion or salt thereof, and a derivative thereof, and a biocompatible polymer are conjugated, where the biocompatible polymer contains a first biocompatible polymer chain and a second biocompatible polymer chain that is different from the first biocompatible polymer chain.

Conjugate and cancer therapeutic agent

A bio-related substance bonded to a branched and degradable polyethylene glycol derivative that is degraded in the cells represented by the following formula (A): wherein each symbol is as defined in the present specification, is provided by the present invention.

Branched degradable polyethylene glycol binder

The invention provides a bio-related substance bonded to a high-molecular-weight polyethylene glycol derivative that does not cause vacuolation of cells. The bio-related substance bonded to a degradable polyethylene glycol derivative is represented by the formula (A): wherein m is 1-7, n1 and n2 are each independently 45-682, p is 1-4, R is an alkyl group having 1-4 carbon atoms, Z is an oligopeptide with 2-8 residues composed of neutral amino acids excluding cysteine, Q is a residue of a compound having 2-5 active hydrogens, D is the bio-related substance, L1, L2, L3, L4 and L5 are each independently a single bond or a divalent spacer, and y is 1-40.

Degradable polyethylene glycol conjugate

The invention provides a high-molecular-weight polyethylene glycol derivative that does not cause vacuolation of cells. The degradable polyethylene glycol derivative is represented by the following formula (1): wherein m is 1-7, n1 and n2 are each independently 45-682, p is 1-4, R is an alkyl group having 1-4 carbon atoms, Z is an oligopeptide with 2-8 residues composed of neutral amino acids excluding cysteine, Q is a residue of a compound having 2-5 active hydrogens, X is a functional group capable of reacting with a bio-related substance, and L, L, L, Land Lare each independently a single bond or a divalent spacer.

Degradable polyethylene glycol derivative

A pH-responsive polymer formed of a biocompatible polymer to which a group which is electrically neutral under pH environments of more than 7 and which changes to be cationic at pH 7 or less is bonded.

PH-responsive polymer and drug delivery system

The present invention pertains to a ligand that contains a plurality of groups represented by formula (1) and is capable of multivalently binding to a glutamine transporter expressed in excess in a cancer cell compared to a normal cell.

Ligand capable of multivalently binding to glutamine transporter, and composition comprising same

The present invention pertains to: a p-boronophenylalanine derivative that comprises a polymer to which a group represented by formula (I) is linked directly or via a linker; a composition containing same; and a kit for producing said derivative and composition.

P-boronophenylalanine derivative and composition containing same, and kit for producing said derivative and composition

The present invention is directed to provide antitumor agent including water-soluble sulfasalazine as an active ingredient. Antitumor agents were obtained with, as the water-soluble sulfasalazine, a PEG-modified sulfasalazine represented by the following formula: wherein an average value of n is 4 or larger and 1136 or smaller.

Antitumor agent

A composition of matter for use in encapsulating a drug is expressed by formula (1) or formula (2): wherein Rand Rare each independently a hydrogen atom or a substituted or unsubstituted, linear or branched alkyl group having 1 to 12 carbon atoms; A is a hydrophilic polymer chain; Land Lare each a linking group; B is a cation-containing group; Ris a side chain of an amino acid; z is an integer of 5 to 500; x is an integer of 40% or more of z; y is 0 or a positive integer; z-x-y is 0 or a positive integer; p is an integer of 1 to 10; and q is an integer of 1 to 10.

Particle composition and pharmaceutical composition using particle composition

Growing community of inventors

Tokyo, Japan

Takahiro Nomoto